BioAge Labs (BIOA) Total Non-Current Liabilities (2023 - 2026)
BioAge Labs (BIOA) posted Total Non-Current Liabilities of $18.1 million for Q1 2026, down 19.64% sequentially from $22.5 million in Q4 2025, and down 40.95% YoY from $30.6 million in Q1 2025.
BioAge Labs (BIOA) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
BioAge Labs has reported Total Non-Current Liabilities for 4 years, with the latest figure at $18.1 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 40.95% year-over-year to $18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (down 40.95% YoY) and the FY2025 annual result came in at $22.5 million, down 35.72% from the prior year.
- Total Non-Current Liabilities slipped to $18.1 million in Q1 2026 per BIOA's latest filing, from $22.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $66.4 million in Q4 2023 and troughed at $18.1 million in Q1 2026.
- A 4-year average of $31.3 million and a median of $27.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities plunged 47.34% in 2024, then grew 19.36% in 2025.
- Over 4 years, Total Non-Current Liabilities stood at $66.4 million in 2023, then slumped by 47.34% to $35.0 million in 2024, then plunged by 35.72% to $22.5 million in 2025, then retreated by 19.64% to $18.1 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $18.1 million, $22.5 million, and $27.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | BioAge Labs | 434.04 Mn | 434.04 Mn | -14.23 Mn | 21.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.34 Mn |
| Mar 31, 2026 | 18.06 Mn |
| Dec 31, 2025 | 22.47 Mn |
| Sep 30, 2025 | 27.48 Mn |
| Jun 30, 2025 | 27.26 Mn |
| Mar 31, 2025 | 30.58 Mn |
| Dec 31, 2024 | 34.95 Mn |
| Sep 30, 2024 | 23.02 Mn |
| Dec 31, 2023 | 66.37 Mn |